https://orcid.org/0000-0002-5996-2090
References
- Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018;73:1393–1414.
- Johansson SGO, Haahtela T. O’Byrne Omalizumab and the immune system: an overview of preclinical and clinical data. Ann Allergy Asthma Immunol 2002;89:132–138.
- Davis LA. Omalizumab: a novel therapy for allergic asthma. Ann Pharmacother 2004;38:1236–1242.
- Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006;117:1493–1499.
- Azhary H, Farooq MU, Bhanushali M, et al. Peripheral neuropathy:differential diagnosis and management. Am Fam Physician 2010;81:887–892.
- Hughes RA. Peripheral neuropathy. BMJ 2002;324:466–469.
- Boulton AJM. Management of diabetic peripheral neuropathy. Clin Diabetes 2005;23:9–15.
- Yavuz GO, Yılgör A, Yavuz IH, et al. Effects of omalizumab therapy on peripheral nevre functions: short observational study. Adv Dermatol Allergol 2019;36:211–216.
- Kalteren WS, Schreurs MWJ, Jorritsma-Smit A, et al. Ocular myasthenic syndrome, adverse reaction to omalizumab? A case report. Br J Clin Pharmacol 2017;83:2330–2332.
- Watson JC, Dyck PJB. Peripheral neuropathy: a practical approach to diagnosis and symptom management. Mayo Clin Proc 2015;90:940–951.
- Alshekhlee A, Basiri K, Miles JD, et al. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists. Muscle Nerve 2010;41:723–727.
- Xolair® (omalizumab) for subcutaneous use package insert. Genentech, Inc. and Novartis Pharmaceutical Corporation; 2003. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103976s5225lbl.pdf
- Abraham A, Barnett C, Katzberg HD, et al. Toronto clinical neuropathy score is valid for a wide spectrum of polyneuropathies. Eur J Neurol 2018;25:484–490.
- Mlynek A, Zalewska-Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria? Allergy 2008;63:777–780.
- American Diabetes Association. Report and recommendations of the San Antonio Conference on diabetic neuropathy. Muscle Nerve 1988;11:661–667.
- Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012;71:2–45.
- Stübgen JP. Tumor necrosis factor—antagonists and neuropathy. Muscle Nerve 2008;37:281–292.
- Fernández-Espartero MC, Pérez-Zafrilla B, Naranjo A, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Sem Arthritis Rheum 2011;40:330–337.
- Jaso R, Sierra M, Calleja J, et al. Guillain-Barré syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association? J Neurol 2010;257:488–489.
- Jachiet M, Samson M, Cottin V. Anti-IgE monoclonal antibody (omalizumab)in refractory and relapsing eosinophilic granulomatosis with polyangiitis (churg-strauss) data on seventeen patients. Arthritis Rheum 2016;68:2274–2282.
- Letz R, Gerr F. Covariates of human peripheral nerve function: I. Nerve conduction velocity and amplitude. Neurotoxicol Teratol 1994;16:95–104.
- Deniz MY, Gupta N. Safety and tolerability of omalizumab (Xolair®), a recombinant humanized monoclonal Anti-IgE antibody. NJ Clin Rev Allergy Immunol 2005;29:31–48.
- Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39:788–797.
- Lieberman P, Rahmaoui A, Wong DA. The safety and interpretability of skin tests with omalizumab. Ann Allergy Asthma Immunol 2010;105:493–495.